The more I look at our results from our initial ASD and Pandas Pans trials :
1)ASD
https://announcements.asx.com.au/asxpdf/20221026/pdf/45gs1jm8ync5k5.pdf
2)Pandas Pans
https://announcements.asx.com.au/asxpdf/20231006/pdf/05vrp7vzjjykl6.pdf
Our latest Presentation
https://announcements.asx.com.au/asxpdf/20231122/pdf/05xmddn5kv3nv0.pdf
And when compared to the latest Phelan McDermind syndrome results and also Retts from Neuron (Neu) -- which I believe we look to have better outcomes in both ASD and Pandas Pans in comparisons about side effects, safety, CGI classification and Vineland assessment.
While Neuron has gone down the more recognised path with synthetic drugs we have a more difficult path and process with a full plant extract.
If we can show the market a way forward to the prescription only market, I believe we will be on a multi billion dollar company.
The Dream
$80m to $800m this year
Or maybe Inevitable
